Top in cardiology: Wegovy cuts major events risk; AHA launches telehealth certification
Click Here to Manage Email Alerts
Injectable Wegovy 2.4 mg was associated with a 20% reduction in the risks for major adverse cardiovascular events among patients with overweight or obesity and established CVD, data show.
Researchers said the data are the first to demonstrate a reduction in hard cardiovascular outcomes for an obesity treatment. It was the top story in cardiology last week.
Another top story centered on the American Heart Association’s first individual certification for telehealth, available through the organization’s professional education hub.
Read these and more top stories in cardiology below:
Topline data show semaglutide cuts CV risk by 20%: SELECT
Compared with placebo, injectable Wegovy (semaglutide, Novo Nordisk) 2.4 mg reduced risk for major adverse cardiovascular events by 20% for people with overweight or obesity and established CVD, according to topline data from the SELECT study. Read more.
‘Telehealth is here to stay’: AHA launches its first individual telehealth certification
The American Heart Association recently launched its first individual certification for telehealth, part of an effort to improve standards of care for a delivery model that grew exponentially — and unevenly — during the COVID-19 pandemic. Read more.
Heart, other organs show mitochondrial damage after COVID-19 despite recovery of lungs
Following SARS-CoV-2 infection, mitochondrial function remained impaired in the heart, liver and kidneys, despite observed recovery in the lungs, according to a human autopsy and animal tissue study. Read more.
AI shows ‘technical and clinical feasibility’ to detect HFpEF from a TTE video clip
Artificial intelligence demonstrated strong diagnostic performance in the detection of heart failure with preserved ejection fraction using a single transthoracic echocardiogram video clip, according to data published in JACC: Advances. Read more.
Remnant cholesterol accumulation tied to risk for atherosclerosis
Data show that higher cumulative remnant cholesterol and greater remnant cholesterol variability are each associated with elevated risk for atherosclerosis, independent of LDL, triglycerides level and other traditional cardiovascular risk factors. Read more.